https://www.selleckchem.com/products/rottlerin.html he potential to improve the detection rate of primary tumor in HNCUP patients with negative FDG findings. Moreover, 68Ga-FAPI had similar performance in assessing metastases with 18F-FDG.The present study aimed to evaluate the feasibility of ultra-low 18F-fluorodeoxyglucose (FDG) activity in total-body positron emission tomography (PET)/computed tomography (CT) oncological studies. Methods Thirty patients with cancer were enrolled prospectively and underwent a total-body PET/CT examination with an ultra-low 18F-FDG activity (0.37 MBq/kg) after an uptake time of 60 minutes. Among the enrolled patients, 11 were diagnosed with colorectal cancer (CRC). PET raw data were acquired within 15 minutes and reconstructed using data from the first 1, 2, 4, 8, 10 and the entire 15 min (G1, G2, G4, G8, G10, G15). Image quality was assessed qualitatively by two readers using a 5-point Likert scale twice. Cohen's kappa test was performed to investigate the intra-reader and inter-reader agreement. The standard uptake value (SUV)max of lesions, SUVmax, SUVmean, and standard deviation (SD) of the livers, the tumor-to-background ratio (TBR), and the signal-to-noise ratio (SNR) were measured and compared. The acqhe ultra-low activity group with an 8-min acquisition and the full activity group with a 2-min acquisition. Conclusion Ultra-low FDG activity injection with 8-min acquisition in a total-body PET/CT study can achieve acceptable image quality equivalent to that in the full activity group using 2-min acquisition. Current evidence indicates that the impact of GeneXpert for diagnosing TB in low- and middle-income countries (LMICs) has not demonstrated equivalent outcomes when compared to Xpert evaluations in upper-middle-income countries. Challenges associated with implementation are possible contributing factors preventing this innovative diagnostic technology from achieving more significant public health outcomes. This review aime